Triglyceride-Glucose Index is Significantly Associated with the Risk of Hyperuricemia in Patients with Nonalcoholic Fatty Liver Disease

References

• Chen‐Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the national health and nutrition examination survey, 2007–2016. Arthritis Rheumatol. 2019;71(6):991–999. doi:10.1002/art.40807
   PubMed Web of Science ®Google Scholar
• Borghi C, Rosei EA, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33(9):1729–1741. doi:10.1097/HJH.0000000000000701
   PubMed Web of Science ®Google Scholar
• Targher G, Byrne CD, Nafld TH. and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691–1705. doi:10.1136/gutjnl-2020-320622
   PubMed Web of Science ®Google Scholar
• She D, Wang Y, Liu J, et al. Changes in the prevalence of hyperuricemia in clients of health examination in Eastern China, 2009 to 2019. BMC Endocr Disord. 2022;22(1):202. doi:10.1186/s12902-022-01118-z
   PubMed Web of Science ®Google Scholar
• Younossi ZM. Non-alcoholic fatty liver disease – a global public health perspective. J Hepatol. 2019;70(3):531–544. doi:10.1016/j.jhep.2018.10.033
   PubMed Web of Science ®Google Scholar
• Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1):S47–S64. doi:10.1016/j.jhep.2014.12.012
   PubMed Web of Science ®Google Scholar
• Doehner W, Landmesser U. Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options. Semin Nephrol. 2011;31(5):433–440. doi:10.1016/j.semnephrol.2011.08.007
   PubMed Web of Science ®Google Scholar
• Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic fatty liver disease and the heart. J Am Coll Cardiol. 2019;73(8):948–963. doi:10.1016/j.jacc.2018.11.050
   PubMed Web of Science ®Google Scholar
• Katsiki N G, Athyros V, Karagiannis A P, Mikhailidis D. Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): a relationship with implications for vascular risk? CVP. 2011;9(6):698–705. doi:10.2174/157016111797484152
   Google Scholar
• Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2(11):901–910. doi:10.1016/S2213-8587(14)70032-4
   PubMed Web of Science ®Google Scholar
• Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013;25(2):210–216. doi:10.1097/BOR.0b013e32835d951e
   PubMed Web of Science ®Google Scholar
• Li S, Fu Y, Liu Y, et al. Serum uric acid levels and nonalcoholic fatty liver disease: a 2-sample bidirectional Mendelian randomization study. J Clin Endocrinol Metab. 2022;107(8):e3497–e3503. doi:10.1210/clinem/dgac190
   PubMed Web of Science ®Google Scholar
• Liu Z, Que S, Zhou L, Zheng S. Dose-response relationship of serum uric acid with metabolic syndrome and non-alcoholic fatty liver disease incidence: a meta-analysis of prospective studies. Sci Rep. 2015;5(1):14325. doi:10.1038/srep14325
   PubMedGoogle Scholar
• Aktas G, Khalid A, Kurtkulagi O, et al. Poorly controlled hypertension is associated with elevated serum uric acid to HDL-cholesterol ratio: a cross-sectional cohort study. Postgrad Med. 2022;134(3):297–302. doi:10.1080/00325481.2022.2039007
   PubMed Web of Science ®Google Scholar
• Kocak MZ, Aktas G, Erkus E, Sincer I, Atak B, Duman T. Serum uric acid to HDL-cholesterol ratio is a strong predictor of metabolic syndrome in type 2 diabetes mellitus. Rev Assoc Med Bras. 2019;65(1):9–15. doi:10.1590/1806-9282.65.1.9
   PubMed Web of Science ®Google Scholar
• Aktas G, Kocak MZ, Bilgin S, Atak BM, Duman TT, Kurtkulagi O. Uric acid to HDL cholesterol ratio is a strong predictor of diabetic control in men with type 2 diabetes mellitus. Aging Male. 2020;23(5):1098–1102. doi:10.1080/13685538.2019.1678126
   PubMed Web of Science ®Google Scholar
• Kosekli MA, Kurtkulagii O, Kahveci G, et al. The association between serum uric acid to high density lipoprotein-cholesterol ratio and non-alcoholic fatty liver disease: the abund study. Rev Assoc Med Bras. 2021;67(4):549–554. doi:10.1590/1806-9282.20201005
   PubMed Web of Science ®Google Scholar
• Kurtkulagi O, Tel BMA, Kahveci G, et al. Hashimoto’s thyroiditis is associated with elevated serum uric acid to high density lipoprotein-cholesterol ratio. Rom J Intern Med. 2021;59(4):403–408. doi:10.2478/rjim-2021-0023
   PubMed Web of Science ®Google Scholar
• Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–1048. doi:10.1016/j.metabol.2015.12.012
   PubMed Web of Science ®Google Scholar
• Yanai H, Adachi H, Hakoshima M, Katsuyama H. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. IJMS. 2021;22(17):9221. doi:10.3390/ijms22179221
   Google Scholar
• Wang J, Yan S, Cui Y, Chen F, Piao M, Cui W. The diagnostic and prognostic value of the triglyceride-glucose index in metabolic dysfunction-associated fatty liver disease (MAFLD): a systematic review and meta-analysis. Nutrients. 2022;14(23):4969. doi:10.3390/nu14234969
   PubMed Web of Science ®Google Scholar
• Zheng R, Du Z, Wang M, Mao Y, Mao W. A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease. Lipids Health Dis. 2018;17(1):262. doi:10.1186/s12944-018-0913-3
   PubMed Web of Science ®Google Scholar
• Guo W, Lu J, Qin P, et al. The triglyceride-glucose index is associated with the severity of hepatic steatosis and the presence of liver fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in Chinese adults. Lipids Health Dis. 2020;19(1):218. doi:10.1186/s12944-020-01393-6
   PubMed Web of Science ®Google Scholar
• Liu XZ, Xu X, Zhu JQ, Zhao DB. Association between three non-insulin-based indexes of insulin resistance and hyperuricemia. Clin Rheumatol. 2019;38(11):3227–3233. doi:10.1007/s10067-019-04671-6
   PubMed Web of Science ®Google Scholar
• Wei CY, Sun CC, Wei JCC, et al. Association between hyperuricemia and metabolic syndrome: an epidemiological study of a labor force population in Taiwan. Biomed Res Int. 2015;2015:1–7.
   Web of Science ®Google Scholar
• Jian-gao F; Chinese Liver Disease Association. Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition. Zhonghua Gan Zang Bing Za Zhi. 2010;18(3):163–166.
   PubMedGoogle Scholar
• Xi B, He D, Hu Y, Zhou D. Prevalence of metabolic syndrome and its influencing factors among the Chinese adults: the China Health and Nutrition Survey in 2009. Prev Med. 2013;57(6):867–871. doi:10.1016/j.ypmed.2013.09.023
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang J, Pu Y, et al. Comparison of different insulin resistance surrogates to predict hyperuricemia among U.S. non-diabetic adults. Front Endocrinol. 2022;13:1028167. doi:10.3389/fendo.2022.1028167
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang Y, Cheng J, et al. Hyperuricemia and cardiovascular disease. CPD. 2019;25(6):700–709. doi:10.2174/1381612825666190408122557
   Google Scholar
• Kimura Y, Tsukui D, Kono H. Uric acid in inflammation and the pathogenesis of atherosclerosis. IJMS. 2021;22(22):12394. doi:10.3390/ijms222212394
   Web of Science ®Google Scholar
• Chen WY, Fu YP, Zhou M. The bidirectional relationship between metabolic syndrome and hyperuricemia in China: a longitudinal study from CHARLS. Endocrine. 2022;76(1):62–69. doi:10.1007/s12020-022-02979-z
   PubMed Web of Science ®Google Scholar
• Li M, Hu X, Fan Y, et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. Sci Rep. 2016;6(1):19520. doi:10.1038/srep19520
   PubMedGoogle Scholar
• Li M, Hou W, Zhang X, Hu L, Tang Z. Hyperuricemia and risk of stroke: a systematic review and meta-analysis of prospective studies. Atherosclerosis. 2014;232(2):265–270. doi:10.1016/j.atherosclerosis.2013.11.051
   PubMed Web of Science ®Google Scholar
• Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922. doi:10.1038/s41591-018-0104-9
   PubMed Web of Science ®Google Scholar
• Fahed G, Aoun L, Bou Zerdan M, et al. Metabolic syndrome: updates on pathophysiology and management in 2021. IJMS. 2022;23(2):786. doi:10.3390/ijms23020786
   Google Scholar
• Fan JG, Zhu J, Li XJ, et al. Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol. 2005;20(12):1825–1832. doi:10.1111/j.1440-1746.2005.04058.x
   PubMed Web of Science ®Google Scholar
• Bence KK, Birnbaum MJ. Metabolic drivers of non-alcoholic fatty liver disease. Molcul Metabol. 2021;50:101143. doi:10.1016/j.molmet.2020.101143
   PubMed Web of Science ®Google Scholar
• Yoo JJ, Cho EJ, Chung GE, et al. Nonalcoholic fatty liver disease is a precursor of new-onset metabolic syndrome in metabolically healthy young adults. JCM. 2022;11(4):935. doi:10.3390/jcm11040935
   Google Scholar
• Guo Z, Zhang T, Yun Z, et al. Assessing the causal relationships between human blood metabolites and the risk of NAFLD: a comprehensive Mendelian randomization study. Front Genet. 2023;28(14):1108086. doi:10.3389/fgene.2023.1108086
   Google Scholar
• Khan RS, Bril F, Cusi K, Newsome PN. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology. 2019;70(2):711–724. doi:10.1002/hep.30429
   PubMed Web of Science ®Google Scholar
• Sun DQ, Jin Y, Wang TY, et al. MAFLD and risk of CKD. Metabolism. 2021;115:154433. doi:10.1016/j.metabol.2020.154433
   PubMed Web of Science ®Google Scholar
• Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol. 2021;75(6):1476–1484. doi:10.1016/j.jhep.2021.08.012
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Bakris GL, Borghi C, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the national kidney foundation. Am J Kidney Dis. 2018;71(6):851–865. doi:10.1053/j.ajkd.2017.12.009
   PubMed Web of Science ®Google Scholar
• Kim K, Kang K, Sheol H, et al. The association between serum uric acid levels and 10-year cardiovascular disease risk in non-alcoholic fatty liver disease patients. IJERPH. 2022;19(3):1042. doi:10.3390/ijerph19031042
   Web of Science ®Google Scholar
• Xu C. Hyperuricemia and nonalcoholic fatty liver disease: from bedside to bench and back. Hepatol Int. 2016;10(2):286–293. doi:10.1007/s12072-015-9682-5
   PubMed Web of Science ®Google Scholar
• Sun DQ, Wu SJ, Liu WY, et al. Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease. Expert Opin Ther Targets. 2016;20(3):375–387. doi:10.1517/14728222.2016.1096930
   PubMed Web of Science ®Google Scholar
• Xu C, Wan X, Xu L, et al. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: one stone hits two birds. J Hepatol. 2015;62(6):1412–1419. doi:10.1016/j.jhep.2015.01.019
   PubMed Web of Science ®Google Scholar
• Fernández‐Chirino L, Antonio‐Villa NE, Fermín‐Martínez CA, et al. Elevated serum uric acid is a facilitating mechanism for insulin resistance mediated accumulation of visceral adipose tissue. Clin Endocrinol. 2022;96(5):707–718. doi:10.1111/cen.14673
   PubMed Web of Science ®Google Scholar
• McCormick N, O’Connor MJ, Yokose C, et al. Assessing the causal relationships between insulin resistance and hyperuricemia and gout using bidirectional Mendelian randomization. Arthritis Rheumatol. 2021;73(11):2096–2104. doi:10.1002/art.41779
   PubMed Web of Science ®Google Scholar
• Nakamura K, Sakurai M, Miura K, et al. HOMA-IR and the risk of hyperuricemia: a prospective study in non-diabetic Japanese men. Diabetes Res Clin Pract. 2014;106(1):154–160. doi:10.1016/j.diabres.2014.07.006
   PubMed Web of Science ®Google Scholar
• Li Q, Shao X, Zhou S, et al. Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease. Sci Rep. 2022;12(1):19988. doi:10.1038/s41598-022-23478-1
   PubMed Web of Science ®Google Scholar
• Liu H, Song X, Zhu J, et al. The elevated visceral adiposity index increases the risk of hyperuricemia in Chinese hypertensive patients: a cross-sectional study. Front Endocrinol. 2022;15(13):18971.
   Google Scholar
• Yang B, Xin M, Liang S, et al. New insight into the management of renal excretion and hyperuricemia: potential therapeutic strategies with natural bioactive compounds. Front Pharmacol. 2022;22(13):1026246. doi:10.3389/fphar.2022.1026246
   Google Scholar
• Gao Z, Zuo M, Han F, et al. Renal impairment markers in type 2 diabetes patients with different types of hyperuricemia. J Diabetes Investig. 2019;10(1):118–123. doi:10.1111/jdi.12850
   PubMed Web of Science ®Google Scholar
• Yan F, Yan S, Wang J, et al. Association between triglyceride glucose index and risk of cerebrovascular disease: systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21(1):226. doi:10.1186/s12933-022-01664-9
   PubMed Web of Science ®Google Scholar
• Tao LC, Xu J, Wang T, Hua F, Li JJ. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol. 2022;21(1):68. doi:10.1186/s12933-022-01511-x
   PubMed Web of Science ®Google Scholar
• Zhu Q, Chen Y, Cai X, et al. The non-linear relationship between triglyceride-glucose index and risk of chronic kidney disease in hypertensive patients with abnormal glucose metabolism: a cohort study. Front Med. 2022;20(9):1018083. doi:10.3389/fmed.2022.1018083
   Google Scholar
• Tutunchi H, Naeini F, Mobasseri M, Ostadrahimi A. Triglyceride glucose (TyG) index and the progression of liver fibrosis: a cross-sectional study. Clin Nutr ESPEN. 2021;44:483–487. doi:10.1016/j.clnesp.2021.04.025
   PubMed Web of Science ®Google Scholar
• Luo Y, Hao J, He X, et al. Association between triglyceride-glucose index and serum uric acid levels: a biochemical study on anthropometry in non-obese type 2 diabetes mellitus patients. DMSO. 2022;15:3447–3458. doi:10.2147/DMSO.S387961
   Google Scholar
• Kahaer M, Zhang B, Chen W, et al. Triglyceride glucose index is more closely related to hyperuricemia than obesity indices in the medical checkup population in Xinjiang, China. Front Endocrinol. 2022;2(13):861760. doi:10.3389/fendo.2022.861760
   Google Scholar